Retatrutide 40
The high-capacity 40 mg Retatrutide pen, same triple-agonist molecule, double the clicks of active per pen.Each click delivers133 µgfrom a 3 mL · 300-click pen.
Featured in these stacks: Advanced Lean Stack, Advanced Summer Stack, Advanced Metabolic Reset.
how many clicks
for your dose?
ThisRetatrutide 40pen holds40 mgacross 300 clicks, so each click delivers133 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why239researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public COA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
Retatrutide 40pen
The high-capacity Retatrutide pen, the same triple GLP-1 / GIP / glucagon agonist at double the total active, for longer research protocols.
"Counted my clicks, done in ten seconds. No syringes, no unit maths, the dosing card lives on my desk now."
"Checked the batch number against the public COA before first use, matched to the decimal. That's why I switched."
"Arrived cold, packed like something precious. Temperature strip still green on arrival. Genuinely impressed."
why a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrivesalready dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence isthird-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a COA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Retatrutide 40 mg Research Pen | Veyvora
The Veyvora Retatrutide 40 mg Research Pen is a batch-documented, cold-chain-dispatched laboratory research item containing 40 mg of retatrutide in a 3 mL, 300-click pen format, supplied for in-vitro research use only. Retatrutide remains an investigational compound with no UK or EU marketing authorisation as of 2026 [3]. This pen is a research procurement item, not a consumer medicine.
This page covers the confirmed format specifications for this pen, what batch documentation Veyvora provides and what requires direct confirmation, and how to procure the pen for in-vitro laboratory research.
Request a GBP quote and current stock status directly from Veyvora before placing an order.
Key Takeaways
- The pen delivers 40 mg of retatrutide across 300 clicks at 133 micrograms per actuation.
- Each pen ships with a batch-specific certificate of analysis (COA); purity figures and identity confirmation require the COA, not the product listing alone.
- Live pricing, stock and shipping appear on the Veyvora product page; request a GBP quote to confirm current figures.
- The pen is classified for in-vitro laboratory research only; no human-use instructions are provided or implied [1][2].
- Retatrutide holds no UK marketing authorisation as of 2026 [3].
How to use a retatrutide pen for laboratory research
- Confirm the batch number on the pen barrel matches the COA supplied with the order before the pen enters any in-vitro protocol.
- Attach a sterile 31G 6 mm pen needle immediately before each use; remove and dispose of it after.
- Dial one click to deliver 133 micrograms (0.133 mg) of retatrutide per actuation, as stated on the printed dosing card included with each pen [1].
- Record the click count against your experimental volume requirements in your laboratory notebook.
- Replace the pen cap and return the pen to 2–8 °C cold storage between sessions.
- Use the pen exclusively for in-vitro laboratory research; no human-use instructions are provided or implied [2].
Price and availability
Request a current GBP quote directly from Veyvora. Veyvora lists dispatch to the UK, EU and South Africa; contact the supplier for current stock status, pricing and country-specific ordering terms, as live figures were not publicly verifiable at the time of writing (30 August 2026) [1][2].
Specification snapshot
| Attribute | Verified value |
|---|---|
| Labelled fill | 40 mg |
| Volume | 3 mL |
| Total clicks | 300 |
| Delivery per click | 133 micrograms (0.133 mg) |
| Needle compatibility | 31G 6 mm pen needles |
| Use classification | In-vitro laboratory research only |
Retatrutide 40 mg Research Pen: product identity and scope
The Veyvora Retatrutide 40 mg Research Pen delivers 40 mg of retatrutide across 300 clicks in a 3 mL multi-dose pen format, with each actuation releasing 133 micrograms, according to the supplier’s 2026 product specification [1][2]. Before first use, verify your batch against the public COA to confirm identity; for the evidential limits of any purity result, see what HPLC purity does and does not prove.
Verified Specifications
Confirmed format data
| Attribute | Verified value | Source |
|---|---|---|
| Labelled fill | 40 mg | Veyvora product page, 2026 [1] |
| Pen volume | 3 mL | Veyvora product page, 2026 [1] |
| Total actuations | 300 clicks | Veyvora product page, 2026 [1] |
| Delivery per click | 133 micrograms (0.133 mg) | Veyvora dosing card, 2026 [2] |
| Pen format | Multi-dose, capped barrel | Veyvora product page, 2026 [1] |
| Batch documentation | Certificate of analysis included | Veyvora product page, 2026 [2] |
Values requiring operator confirmation
The attributes below are not confirmed on publicly accessible pages reviewed as of 30 August 2026 and should be verified directly with Veyvora before procurement decisions are made:
- Excipient composition and buffer details
- Assay tolerance ranges and acceptance criteria
- Reconstitution vehicle, if applicable
- Shelf life from date of manufacture
Purity figures and identity confirmation depend on the batch-specific COA rather than on the product listing alone. For compound background relevant to selecting this pen for a specific in-vitro protocol, see the retatrutide research and receptor profile. Cold-chain and stability parameters are covered separately in the storage and stability guidance.
Batch documentation and analytical evidence
Veyvora states that each Retatrutide 40 mg Research Pen ships with a batch-specific COA and that the product is independently assayed, according to the supplier’s 2026 product specification [1][2]. The underlying COA file, chromatogram, and numeric assay table are not exposed on publicly accessible pages reviewed as of 30 August 2026 [1][2].
What the batch documentation covers
Veyvora’s public listing confirms the following documentation is offered with each pen [1][2]:
- A batch COA linked to the pen’s batch number
- Independent verification by Asterion Analytics, then again by Veyvora’s own internal testing (Veyvora, 2026) [2]
- A dosing card stating 133 micrograms per click across 300 actuations [2]
What the documentation cannot confirm without the COA
The values below are not verifiable from the public product page alone and require the batch-specific COA before any in-vitro protocol decision is made [1][2]:
- Numeric purity percentage and assay tolerance range
- Identity confirmation method (e.g. high-performance liquid chromatography (HPLC), mass spectrometry (MS))
- Acceptance criteria applied at release
- Excipient or buffer composition
Researchers procuring this pen for in-vitro work should request the COA directly from Veyvora and cross-reference the batch number before the pen enters any protocol. For compound-selection context across related investigational agents such as tirzepatide or semaglutide, see the retatrutide versus tirzepatide comparison.
Handling and storage
Handling and storage instructions for the Veyvora Retatrutide 40 mg Research Pen are not confirmed on publicly accessible product pages reviewed as of 30 August 2026 [1][2]. The values below require operator confirmation before any in-vitro protocol begins.
What to confirm before use
Retrieve the batch-specific product insert or COA from Veyvora before handling the pen. The following parameters are standard for peptide research materials but must be verified against the batch document rather than assumed from general guidance [1][2]:
- Storage temperature, confirm from batch insert; not verified on public page
- Transport conditions, confirm from batch insert; not verified on public page
- In-use stability window, confirm from batch insert; not verified on public page
- Reconstitution requirements, confirm from batch insert; not verified on public page
Veyvora states that each pen ships with a batch COA [1][2], which is the authoritative source for temperature, stability, and handling parameters specific to the pen’s formulation.
Ordering information
No verified GBP price, live stock level, dispatch speed, or country-specific shipping charge for the Veyvora Retatrutide 40 mg Research Pen could be confirmed from publicly accessible pages reviewed as of 30 August 2026 [1][2]. Those commercial details require direct confirmation with Veyvora before procurement decisions are made.
What is confirmed
The following product-scope facts are supported by Veyvora’s public listing as of 30 August 2026 [1][2]:
- The item is listed as a research pen with a labelled fill of 40 mg retatrutide in a 3 mL, 300-click format.
- Each pen is presented as batch-numbered and supplied with a COA.
- The product is offered for laboratory research procurement, not consumer or clinical purchase.
- Pricing, stock availability, and delivery terms are unverified and must be confirmed directly via the Veyvora product page or distributor contact.
Before placing an order
Prospective laboratory buyers should request the current batch COA before committing to a purchase, because purity and identity data are batch-specific and cannot be inferred from the product listing alone. Post-delivery requirements are covered in the storage and stability guidance, which addresses the 2–8 °C cold-chain conditions relevant once the pen arrives. Researchers who need compound background before selecting the product can consult the retatrutide research and receptor profile for published-evidence context.
Contact Veyvora directly to request a GBP quote, confirm current stock, and obtain the batch COA before committing to an order.
Research-use-only limitations
The Veyvora Retatrutide 40 mg Research Pen is classified as a laboratory research product and is not presented as a medicine, treatment, or consumer health item [1][2]. Retatrutide holds no UK marketing authorisation as of 2026, meaning no clinical sale to consumers is authorised [3][4].
No public-facing page reviewed as of 30 August 2026 provides human-use instructions, administration protocols, dose targets, or outcome claims for this pen [1][2][3].
What this classification excludes
Procurement, handling, and analytical decisions for the Veyvora Retatrutide 40 mg Research Pen must remain within the following boundaries:
- The pen is supplied for in-vitro laboratory research only; it is not for human administration [1][2].
- No therapeutic benefit, clinical efficacy, or personal suitability claim is supported by the product listing [1][2][3].
- Dose-target calculations and administration protocols fall outside the scope of this product page and must not be inferred from labelled fill or click-count data [1][2].
- Any procurement framing should reflect the investigational status of retatrutide and the research-only category in which Veyvora lists the pen [1][2][4].
Related research and comparison pages
Veyvora places the Retatrutide 40 mg Research Pen within its Metabolic & Weight research-pen category, so comparison decisions should focus on format attributes such as labelled fill, click-count structure, and batch documentation rather than on clinical or efficacy claims [1][2].
Researchers selecting between investigational compounds, including tirzepatide, semaglutide, or other GLP-1-class agents, can consult the retatrutide versus tirzepatide comparison for format and specification context. Those who have not yet confirmed a specific product can browse the metabolic research peptide catalogue for the broader range of available research pens.
No head-to-head analytical comparison between the Retatrutide 40 mg pen and other research pens is currently verifiable from public pages reviewed as of 30 August 2026 [1][2]; any such comparison should be sourced from batch documentation rather than inferred from product listings.
Sources
[1] Retatrutide 40 mg Pen | Veyvora, veyvora.com, https://veyvora.com/peptides/retatrutide-40 [2] Metabolic & Weight Research Pens | Veyvora, veyvora.com, https://veyvora.com/categories/metabolic [3] Medicines and Healthcare products Regulatory Agency (MHRA) products register, gov.uk, https://products.mhra.gov.uk/ [4] Veyvora research peptides, veyvora.com, https://veyvora.com/
